LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or “the Company”) (NASDAQ: RAPT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RAPT is the subject of a report by Marketwatch that, “regulators have hit pause on two clinical trials of its experimental inflammation treatment due to liver failure in a trial participant.” Based on this news, shares of RAPT were done more than 40% in intraday trading on May 9, 2024.
We encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
- HostColor Expands Unmetered Bare Metal Server Offerings - May 9, 2025
- AMA Names Dr. John Whyte Next CEO/EVP - May 9, 2025
- Shareholders’ Meetings of 9 May 2025 - May 9, 2025
